Abstract:Journal of Endovascular Therapy, Ahead of Print. Purpose:Surgical thromboendarterectomy has been the gold standard treatment for common femoral artery (CFA) disease. However, endovascular therapy (EVT) is conducted in certain patients with CFA lesions because of multiple comorbidities. The interwoven nitinol stent (IWS) has been developed to prevent stent fracture. Thus, this study aimed to evaluate the feasibility of EVT using IWS for CFA lesions in clinical practice.Materials and methods:This retrospective multicenter registry analyzed patients who had symptomatic lower-extremity artery disease due to CFA lesions and underwent EVT using IWS between 2019 and 2021. The primary endpoint was restenosis 2 years after EVT.Results:This study enrolled a total of 177 patients with 196 CFA lesions. The 2-year estimate of freedom from restenosis was 88.0%. The 2-year freedom rates from the target-lesion revascularization, major amputation, and all-cause death were 92.9%, 99.0%, and 75.2%, respectively. The clinical features significantly associated with restenosis risk were the reference vessel diameter (RVD, per 1.0 mm, hazard ratio [HR], 0.24 [0.08–0.70]; p=0.009), external iliac artery (EIA) involvement (HR=4.03 [1.56–10.4]; p=0.004), superficial femoral artery (SFA) involvement (HR=3.05 [1.00–9.25]; p=0.049), body mass index (BMI; per 1.0, HR=0.85 [0.73–0.99]; p=0.032), occlusion of deep femoral arteries (DFAs) at baseline (HR=7.89 [2.04–30.5]; p=0.003), and chronic limb-threatening ischemia (CLTI, HR=2.63 [1.02–6.78]; p=0.045). Their significant association was also confirmed by the random survival forest analysis. During a median follow-up of 12.0 months, guiding sheaths were inserted via CFAs implanted IWSs in 73 cases (37.2%), and no patients had cannulation-related complications, such as failed hemostasis, fracture of IWS, and stent occlusion.Conclusions:Endovascular therapy using IWS in CFA lesions showed acceptable 2-year patency rates at 88.0% and might preserve the arterial access via the ipsilateral CFAs. Small RVD, involving EIA and SFA lesions, emaciation, occluded DFA, and CLTI are associated with poor 2-year patency rates following EVT, thus, IWS implantation in CFA lesions may be an option for patients unsuitable for surgical revascularization.Clinical ImpactThis retrospective multicenter registry enrolled 177 patients with 199 CFA lesions treated with EVT using interwoven nitinol stents, because surgical thromboendarterectomy was difficult due to their multiple comorbidities. The 2-year estimate of freedom from restenosis was acceptable at 88.0%. The 2-year freedom rate from major amputation was also high at 99.0%. Moreover, during a median follow-up of 12.0 months, guiding sheaths were inserted via CFAs implanted IWSs in 73 cases, and no patients had cannulation-related complications such as failed hemostasis, fracture of IWS, and stent occlusion.

Three‐year outcomes of contemporary endovascular treatment in over 25‐cm femoropopliteal artery disease from a retrospective multicenter registry: A retrospective observational study

Treatment extent of femoropopliteal disease and clinical outcomes following endovascular therapy

Multicenter Registry of Common Femoral Artery Disease Treated With Endovascular Revascularization Using Interwoven Nitinol Stents: An Observational Retrospective Study

Endovascular Nitinol Stenting for Long Occlusive Disease of the Superficial Femoral Artery in Critical Limb Ischemia: A Single-Center, Mid-Term Result

Endovascular treatment for symptomatic stent failures in long-segment chronic total occlusion of femoropopliteal arteries.

Endovascular Interventions for Transatlantic Intersociety Consensus Ii C and D Femoropopliteal Lesions

Clinical outcomes of endovascular therapy for chronic limb-threatening ischemia in renal transplant recipients

Clinical outcomes and predictors of restenosis in patients with femoropopliteal artery disease treated using polymer-coated paclitaxel-eluting stents or drug-coated balloons

Three-year clinical course after fluoropolymer-based drug-eluting stent implantation for femoropopliteal lesions

Intravascular Lithotripsy and Drug-Coated Balloon Angioplasty for Severely Calcified Femoropopliteal Arterial Disease

Viabahn Stent Graft for the Endovascular Treatment of Occlusive Lesions in the Femoropopliteal Artery: A Retrospective Cohort Study with 4-Year Follow-Up

Endovascular treatment of femoropopliteal atherosclerotic occlusive disease

Endovascular therapy of long occlusive femoral artery

Five-year outcomes of the GORE VIABAHN Endoprosthesis for the treatment of complex femoropopliteal lesions from a Japanese postmarket surveillance study

Clinical impact of fluoropolymer-based drug-eluting stent thrombosis in femoropopliteal artery occlusive lesions

Impact of intravascular ultrasound‐guided endovascular therapy on periprocedural outcomes in patients with lower‐extremity artery disease

Bypass Grafting vs Endovascular Therapy in Patients With Non-Dialysis-Dependent Chronic Kidney Disease and Chronic Limb-Threatening Ischemia (CRITISCH Registry)

Infrapopliteal Surgical and Endovascular Intervention

Short Term Outcomes of a Prospective Registry in Popliteal and Infrapopliteal Endovascular Interventions for Chronic Limb Threatening Ischaemia

The clinical efficacy of endovascular intervention for femoropopliteal arteriosclerosis

Long-term results of extensive aortoiliac occlusive disease (EAIOD) treated by endovascular therapy and risk factors for loss of primary patency